Affimed N.V. (AFMD)

$0.18 -0.10 (-34.95%)
Market Cap 2.92M
Revenue (ttm) 8.96M
Net Income (ttm) -114.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,279.69%
Debt to Equity Ratio 0.47
Volume 23,468,002
Avg Vol 19,511,936
Day's Range N/A - N/A
Shares Out 16.10M
Stochastic %K 15%
Beta 2.07
Analysts Sell
Price Target $6.83

Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, wh...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 621 560030
Fax: 49 621 56003 649
Address:
Gottlieb-Daimler-Straße 2, Mannheim, Germany
Hodl707
Hodl707 Mar. 21 at 3:22 AM
$AFMD Gilde already knew: ∙ The IP was going to transfer to the N.V. ✓ ∙ Roche was going to keep running trials ✓ ∙ Nature Medicine was going to publish ✓ ∙ AFM28 was going to show 40% CR at ASH ✓ ∙ The RMAT designation was going to survive ✓ ∙ The platform was going to emerge clean on the other side ✓ They knew all of that before anyone else did.
0 · Reply
Hodl707
Hodl707 Mar. 20 at 11:21 PM
$AFMD sussane speiler !!! If in fact there’s a fee settlement!!! That means what ?? Anyone ??
0 · Reply
Hodl707
Hodl707 Mar. 20 at 5:57 PM
$AFMD so anything about this March 16 court doc !!
0 · Reply
Hodl707
Hodl707 Mar. 20 at 5:25 AM
$AFMD Gilde’s LPs didn’t just give them €740 million to make money. They gave them €740 million to change medicine. Letting Affimed’s platform die in a $4.5M fire sale to MD Anderson would be a betrayal of every LP commitment Gilde made when they raised Fund VI. They cannot let this die. Their fund mandate won’t allow it. Their LP relationships depend on it. Their reputation as Europe’s premier healthcare impact investor is built on it.
0 · Reply
Hodl707
Hodl707 Mar. 19 at 5:06 PM
$AFMD bootstrap inherited Affimed a debt it wasn’t a original creditor!!
0 · Reply
Hodl707
Hodl707 Mar. 19 at 3:36 PM
$AFMD Kirkland & Ellis is officially advising Affimed on the German insolvency.
1 · Reply
Hodl707
Hodl707 Mar. 19 at 5:38 AM
$AFMD  Kirkland & Ellis !!!!!! What dis mean to any one !!
0 · Reply
Hodl707
Hodl707 Mar. 18 at 11:40 PM
$AFMD Think about this for sec!! Let me know what you tjink ! MD Anderson being on that list wasn’t them trying to grab it. It was them having a seat at the table to make sure it went somewhere the science could survive.
0 · Reply
Hodl707
Hodl707 Mar. 17 at 5:54 PM
$AFMD is it over and done we at 0 !!!
2 · Reply
Hodl707
Hodl707 Mar. 11 at 10:49 AM
$AFMD If you’re Gilde, sitting on Affimed’s RMAT-designated NK cell IP, waiting to house it in Catalym — why would you rush a transaction under the most hostile FDA biologics regulator in recent memory? You wouldn’t. You’d wait. And now Prasad is gone. The regulatory environment just got materially friendlier for exactly this type of novel biologic platform.
0 · Reply
Latest News on AFMD
No data available.
Hodl707
Hodl707 Mar. 21 at 3:22 AM
$AFMD Gilde already knew: ∙ The IP was going to transfer to the N.V. ✓ ∙ Roche was going to keep running trials ✓ ∙ Nature Medicine was going to publish ✓ ∙ AFM28 was going to show 40% CR at ASH ✓ ∙ The RMAT designation was going to survive ✓ ∙ The platform was going to emerge clean on the other side ✓ They knew all of that before anyone else did.
0 · Reply
Hodl707
Hodl707 Mar. 20 at 11:21 PM
$AFMD sussane speiler !!! If in fact there’s a fee settlement!!! That means what ?? Anyone ??
0 · Reply
Hodl707
Hodl707 Mar. 20 at 5:57 PM
$AFMD so anything about this March 16 court doc !!
0 · Reply
Hodl707
Hodl707 Mar. 20 at 5:25 AM
$AFMD Gilde’s LPs didn’t just give them €740 million to make money. They gave them €740 million to change medicine. Letting Affimed’s platform die in a $4.5M fire sale to MD Anderson would be a betrayal of every LP commitment Gilde made when they raised Fund VI. They cannot let this die. Their fund mandate won’t allow it. Their LP relationships depend on it. Their reputation as Europe’s premier healthcare impact investor is built on it.
0 · Reply
Hodl707
Hodl707 Mar. 19 at 5:06 PM
$AFMD bootstrap inherited Affimed a debt it wasn’t a original creditor!!
0 · Reply
Hodl707
Hodl707 Mar. 19 at 3:36 PM
$AFMD Kirkland & Ellis is officially advising Affimed on the German insolvency.
1 · Reply
Hodl707
Hodl707 Mar. 19 at 5:38 AM
$AFMD  Kirkland & Ellis !!!!!! What dis mean to any one !!
0 · Reply
Hodl707
Hodl707 Mar. 18 at 11:40 PM
$AFMD Think about this for sec!! Let me know what you tjink ! MD Anderson being on that list wasn’t them trying to grab it. It was them having a seat at the table to make sure it went somewhere the science could survive.
0 · Reply
Hodl707
Hodl707 Mar. 17 at 5:54 PM
$AFMD is it over and done we at 0 !!!
2 · Reply
Hodl707
Hodl707 Mar. 11 at 10:49 AM
$AFMD If you’re Gilde, sitting on Affimed’s RMAT-designated NK cell IP, waiting to house it in Catalym — why would you rush a transaction under the most hostile FDA biologics regulator in recent memory? You wouldn’t. You’d wait. And now Prasad is gone. The regulatory environment just got materially friendlier for exactly this type of novel biologic platform.
0 · Reply
Think_Bigly
Think_Bigly Mar. 8 at 9:59 PM
$AFMD - This is particularly important for R/R HL patients, especially those who are double-refractory, as there are currently no approved therapies for this group.
0 · Reply
Think_Bigly
Think_Bigly Mar. 8 at 9:55 PM
$AFMD I still believe Gilde is in control of the float.. and paying minimal operating costs in order to maintain key trials. Why? The probability of $B FCF is very high. - Key Implications of RMAT The RMAT designation is a significant regulatory milestone that provides several benefits to accelerate the therapy's development: Enhanced FDA Interaction: It allows for more frequent and earlier meetings with the FDA to discuss development plans and potential surrogate endpoints. Expedited Pathways: It opens the door for potential accelerated approval and priority review of a future Biologics License Application (BLA)... contd..
0 · Reply
Think_Bigly
Think_Bigly Mar. 7 at 8:34 PM
$AFMD ... Roche contd.. - The partnership continues to explore other candidates, including AFM24, a tetravalent bispecific engaging NK cells, in combination with Roche’s Tecentriq (atezolizumab), with a Phase 1/2a trial ongoing. Thus, while specific assets have been discontinued, the overall alliance between Roche and Affimed is still operational.
0 · Reply
Think_Bigly
Think_Bigly Mar. 7 at 8:32 PM
$AFMD from Brave AI .. -Roche has not terminated its partnership with Affimed, but it has discontinued certain development programs under their collaboration. In July 2021, Roche announced the discontinuation of RG6296 (AFM26), a bispecific antibody targeting BCMA for multiple myeloma, developed under the Affimed collaboration. This decision was driven by intense competition in the BCMA space, with advanced CAR-T therapies and other bispecifics demonstrating strong efficacy. Despite Affimed’s promising NK cell-engaging platform, the project was halted due to the high bar for differentiation in this therapeutic area. Roche also discontinued two gene therapy programs licensed from 4D Molecular (4D-110 and 4D-125) due to a "change in risk-benefit profile," which affected the broader ophthalmology gene therapy landscape. However, the core strategic collaboration between Roche (via Genentech) and Affimed remains active.
0 · Reply
Hodl707
Hodl707 Mar. 6 at 5:09 AM
$AFMD
0 · Reply
Think_Bigly
Think_Bigly Mar. 6 at 2:28 AM
$AFMD I still think Gilde bought the sh*t out of this 5/16 - 5/19 of 2025.
1 · Reply
Hodl707
Hodl707 Mar. 6 at 1:11 AM
$AFMD one fact stands if this was a normal liquidation, the NV parent would have been disabled by now !! gilde healthcare still shows its portfolio why the site has been updated not NV but Gilde site so you can’t tell me they forgot about it !!
0 · Reply
deathknight
deathknight Mar. 5 at 6:41 PM
$AFMD folks, Claude from Anthropic is simply amazing! I feed it a few publicly available facts: Gilde anchored 2022 offering and bought 6% of common shares; $AFMD stopped doing ATM ever since (they did ATM every year before that) and the company rather layoff R&D staffs and its CEO without tapping ATM; Gilde keeps those shares instead of dumping prior/after insolvency -- unlike all other intuitional investors. Claude independently "deduced" that the most likely reason for Gilde is to conduct a reverse merger with one of its portfolio companies. I then asked if Catalym is a good fit for the merger and Claude not only aligned both companies scientifically (assuming $AFMD keeps some IPs after the proceeding); it also did more corroborative thinking and pointed to me that a recent CFO appointment at Catalym could be a sign of this reverse merger. Surely no one knows the future and Claude can be wrong but it thought process is so impressive -- it's the best IMO.
2 · Reply
Hodl707
Hodl707 Mar. 3 at 12:16 AM
$AFMD I mean what’s left no info nothing won’t close my position till end of year that’s all !!
0 · Reply
deathknight
deathknight Feb. 27 at 4:54 PM
$AFMD This is why I firmly believe Grok is the worst AI bot out there. All Affimed's clinical trials had been terminated last June/July, including Acimtimag/AB101 combo -- the one with RMAT designation (https://clinicaltrials.gov/study/NCT05883449?intr=AFm13&rank=5&tab=results). It's public information and super easy to verify but Grok still messed up. Totally untrustworthy and useless.
1 · Reply
Think_Bigly
Think_Bigly Feb. 27 at 3:26 AM
$AFMD - Another distinct possibility. -grok:- Acimtimag Early Approval- Overall, with RMAT and Fast Track, strong early efficacy (high ORR/CR in heavily pretreated patients), and favorable safety, the regimen has a promising accelerated approval pathway if expansion cohorts or further data confirm these results. Full approval would likely follow Phase 3 validation. The study remains ongoing (as of recent updates in 2025), with no approval granted yet. Continued enrollment and updated results will be key.
1 · Reply
Think_Bigly
Think_Bigly Feb. 25 at 4:36 AM
Huge future cash flow...​ $AFMD >> $ARTV >> Roche
0 · Reply